(The Center Square) – U.S. Rep. Marjorie Taylor Greene, R-Ga., has been appointed to lead a subcommittee dedicated to working with President-elect Donald Trump’s new Department of Government Efficiency. Known as a Republican firebrand and close ally of Trump, Greene has already set her sights on rooting out “every penny of waste and abuse.” “We’ll be looking at everything from government-funded media programs like NPR that spread nothing but Democrat propaganda, we’ll be going into grant programs that fund things like sex apps in Malaysia, toilets in Africa,” she said on a media appearance Sunday morning. The subcommittee will be under the House Committee on Oversight and Accountability, which is chaired by U.S. Rep. James Comer, R-Ky. “We want to make the government more efficient,” Comer said on a media appearance . “We want to work for the taxpayers, not the bureaucrats. We hate the deep state, we’ve dealt with the deep state, we’ve fought the deep state.” He added that Republicans are excited to implement the recommendations of DOGE, which, as an advisory committee, will have to work with Trump and Congress to change policies. “What Trump has ... are willing partners to make government more efficient,” Comer said of Congress. Elon Musk, CEO of X and Tesla Motors, and Vivek Ramaswamy are currently heading up DOGE. “Looking forward to working together with Congress,” Ramaswamy said on social media of Greene’s appointment . “Proper oversight of agencies and public transparency are critical.” DOGE has made it a key part of its plan to address the national debt of $36 trillion. That is $273,000 owed per taxpayer. “This trend must be reversed, and we must balance the budget,” DOGE posted . For her part, Greene has promised to “drain the swamp,” stating that “nothing is off the table” when it comes to holding government agencies like the Pentagon accountable. “Our government should steward every single cent of your hard-earned money,” Greene said. “The DOGE subcommittee will expose the waste and bring truth and transparency to the American people.” Bureaucrats and independent contractors will also be on the chopping block, in what Greene called a “once-in-a-lifetime opportunity to make real transformational change to government to benefit the American people.” “In the private sector, if you’re not doing a good job, you get fired,” she said on social media . “But for some reason, in government, bad employees – whether they’re failing to do the job they were hired to do or working in roles that are no longer needed – never get fired. This is incredibly unfair to the hard-working taxpayers of our country, and it’s about to change.” Recently, an audit of the IRS found that its employees and contractors owe millions in taxes, all while the agency warned thousands of taxpayers that they could face jail time. “The same unelected IRS government employees and contractors, who owe $50 million in unpaid taxes, would throw Americans in jail for not paying their taxes,” Greene said of the audit . “Time to hold them all accountable.” Greene also addressed Democrats' accusations that the subcommittee will go after programs like Social Security. “No, Senator Warren, we are not going to take away a senior’s Social Security. That’s a lie,” Greene responded on social media . “We are going to investigate all areas of the federal government like CFPB, an ‘independent’ agency inside the federal government. Beholden to no one. Ran by unelected bureaucrats.”THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
Passengers at Newcastle International Airport have reported that the runway was "decimated" by snow as Storm Bert brings heavy winds, rain, and continued snow and icy conditions. Weather warnings are in place, indicating a "potential risk to life and property", with some flights from Newcastle to European destinations facing delays or cancellations. Tim Harding, 53, and his wife Chona, 58, frequent fliers, were meant to depart at 9.15am on a KLM flight to Amsterdam before connecting to a Delta airlines flight to Orlando, Florida, to join family for Thanksgiving in the US. The couple reached the airport around 6am on Saturday, describing the weather conditions as "unprecedented" with snow falling "really quick" within a two-hour window. Mr Harding said that even as they drove towards the airport, the weather deteriorated rapidly: "Going to the airport... it was sleeting all the way through then all of a sudden it started coming down." Despite the efforts of numerous snow ploughs on the runway, their attempts to clear the snowfall were ineffective due to the fast accumulation and windy conditions: "There were about four or five snow ploughs on the runway and they just couldn’t clear it. It was windy and it was literally coming down really quick, so hard. In the space of two hours, it went from nothing to decimated." "The gritters were out continuously, the ploughs were out continuously, but it just wasn’t having an impact unfortunately. I was surprised how quickly it came down and how much came down in a two-hour period. I haven’t seen that for a long time." Although caught off guard by the severity of the weather, Mr Harding commended the airport staff for their diligent efforts in trying to keep the runway clear. "I think the airport did well. I think it was unprecedented... I think they were taken by surprise". The couple were due to meet their 16 year old nephew from Seattle in Amsterdam before joining him on a flight to Orlando, but they have rebooked their trip for Sunday. Despite the cancellation, Mr Harding said his family’s safety is "paramount". He added: "We’re frequent flyers and safety is absolutely paramount for me. You don’t want to jeopardise anybody or put anybody at risk." Fellow holidaymaker Richard Green, whose 9.05am flight for Krakow in Poland has been delayed, said he "couldn’t see the apron" – the area where aircraft park, unload, refuel and are boarded by passengers – which was covered in a blanket of snow. The 25 year old from Wallsend said: "I was coming up on the Metro this morning, it was a bit of sleet, but it wasn’t bad." "It was just as you were getting closer to the airport you could see the snow was starting to lie and then by the time I got into the departure lounge you could see the snow was getting really, really heavy. You couldn’t see the apron. You couldn’t see anything. It was just all white." Mr Green said his flight had been delayed to 3.15pm and was waiting at the airport for further updates. Newcastle International Airport has declared that the runway was cleared by noon on Saturday and efforts are being made to prevent additional delays for its passengers. Sharing an update on their social media platform, the airport communicated: "Due to Storm Bert there has been some disruption to flights this morning due to snowfall in parts of the UK, including Newcastle. "Thanks to our hardworking snow team the runway has been cleared within an hour and the airport is operating as normal. Passengers are still advised to visit our website for the latest flight information and to contact their airline directly if they have any queries." Join our Breaking News and Top Stories WhatsApp community for all the latest news direct to your phone. To join you need to have WhatsApp on your device. All you need to do is choose which community you want to join, click on the link and press 'join community'. No one will be able to see who is signed up and no one can send messages except the ChronicleLive team. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you’re curious, you can read our privacy notice . CLICK HERE TO JOIN
A clean sweep: Trinamool Congress wins all 6 Assembly seats in Bengal bypollsTransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial OutlookTrump Pick of Billionaire Feinberg for Pentagon Bolsters Hegseth
Provident Bancorp, Inc. Adopts Stock Repurchase Program
Compass, Christie's International Real Estate, @properties, and Ansley Real Estate Agree to Join ForcesNone
